These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 13571602)

  • 1. In vitro and in vivo effect of antimicrobial agents on atypical mycobacteria.
    STEENKEN W; SMITH MM; MONTALBINE V
    Am Rev Tuberc; 1958 Sep; 78(3):454-61. PubMed ID: 13571602
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
    Casal M; Gutierrez J; Ruiz P; Moreno G
    Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activities of quinolones against mycobacteria.
    Garcia-Rodriguez JA; Gomez Garcia AC
    J Antimicrob Chemother; 1993 Dec; 32(6):797-808. PubMed ID: 8144420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
    Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
    J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for determining the antimicrobial susceptibility of mycobacteria.
    Alcaide F; Esteban J; González-Martin J; Palacios JJ
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):529-535. PubMed ID: 27236235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
    Marinis E; Legakis NJ
    J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising new drugs in the treatment of tuberculosis and mycobacteriosis.
    Casal M; Rodríguez F; Gutierrez J; Ruiz P; Benavente MC; Villalba R; Moreno G
    J Chemother; 1989 Feb; 1(1):39-45. PubMed ID: 2498468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of atypical mycobacteria to cephalosporins.
    Garcia-Rodriguez JA; Martin-Luengo F
    Tubercle; 1980 Mar; 61(1):39-40. PubMed ID: 7368324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in the bacteriology of tuberculosis (including drug resistance and atypical Mycobacteria).
    Laidlaw M
    Scott Med J; 1978 Apr; 23(2):181. PubMed ID: 644301
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro susceptibility of mycobacteria, especially of Mycobacterium intracellulare, to 5-fluorouracil and pattern of development of resistance of Mycobacterium tuberculosis to the drug.
    Tsukamura M
    Microbiol Immunol; 1979; 23(5):427-9. PubMed ID: 116112
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.
    Berlin OG; Young LS; Floyd-Reising SA; Bruckner DA
    Eur J Clin Microbiol; 1987 Aug; 6(4):486-7. PubMed ID: 2959472
    [No Abstract]   [Full Text] [Related]  

  • 13. A drug sensitivity test strategy for atypical mycobacteria.
    Hejný J
    Tubercle; 1982 Mar; 63(1):63-9. PubMed ID: 7082424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Mycobacterium marinum to dihydromycoplanecin A and ten other antimicrobial agents.
    Arai H; Nakajima H; Kaminaga Y
    J Dermatol; 1990 Jun; 17(6):370-4. PubMed ID: 2384640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Mycobacterium abscessus Infection.
    Novosad SA; Beekmann SE; Polgreen PM; Mackey K; Winthrop KL;
    Emerg Infect Dis; 2016 Mar; 22(3):511-4. PubMed ID: 26890211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.
    Kuze F; Kurasawa T; Bando K; Lee Y; Maekawa N
    Rev Infect Dis; 1981; 3(5):885-97. PubMed ID: 7339820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
    Casal M; Rodriguez F; Benavente M; Luna M
    Eur J Clin Microbiol; 1986 Aug; 5(4):453-4. PubMed ID: 3093225
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro susceptibility to antibiotics and sulfonamides of atypical mycobacteria isolated in South America.
    de Kantor IN; Barrera L; di Lonardo M
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Oct; 260(2):247-53. PubMed ID: 4082825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
    Easmon C; Verity L
    Eur J Clin Microbiol; 1987 Apr; 6(2):165-6. PubMed ID: 3109896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.